9501药师国考调剂学

  • 格式:pdf
  • 大小:201.26 KB
  • 文档页数:4

95年󰲃󰎋󰔛󰮑󰟐󱙍󰽰󰏷󰗞󰳌󰎓󰦩󰬯󰸻󱄤󰶯󰳯󰔵󱁂󱙴󰙣󰎓󰦩󰇵

󰏍󱙴󰧣󰇵󰐈理󰧣󰇵󰚥󰖎󰝯療󰧣󰇵󱔼󱎦󰧣󰇵󱛌󱙴󰎓󰦩󰔵󱁂󱁂󱚒

󰸻 󰕱󰇺󰬯󰸻󰔵󱁂

類 󰣽󰇺󱛰󰧣

󰣽󰀡󰀡󰒞󰇺󱍓󱏊󱏢󰈐󰑅󰡴臨󰗉󱛰󱏢󱆶󰝯療󱏢󰈑

󰔵󱁂󰨔󰻔󰇺1󰎻󰨔 󰧦󱀦󰇺󰀡󰀡󰀡󰀡󰀡󰀡󰀡

󰉁󰝙󰽀󰇺 󰒁󱁂󱚒󰣁󰵂󰎋󱒧󱏷󱚒󰇴󱍎󱒧󰑀󰎋󰦁󰒅󱋴󰜈󰴨󱍾󰾽󰞑󰹀󰨢󰇴󱍄󱒧󰕢󰹀󰞣󰇴󱁀󱚒不󰏒󰥀󰏩󰇶

󰒁󰣽󰒞󰓅80󱚒󰇴󰘂󱚒1.25󰏩󰇴󰻪󰒔2󰋾󱂉󰸽󰓧󱁂󰑌󰎢󰙩󱚒󱀦󰰮󰽱󱃄󰫶󰇴󰜭󰒁󱁂󱚒󰎢󰕢󰹀󰞣󰇴不󰏒󰥀󰏩󰇶

󰒁󱁂󱚒󰿣󰐗󰙬󰒔󱂝󰎷󰥀󱆉󱏔󰇶 󰐶󱀦󰇺4104

󰥤󰔛󰇺4󰉡1

1 Chloramphenicol󰖗Mydrilate®󰿛󱋠󰸓󱕪󰎰eye drops󰎱󰕰󰻈󱔞󰡵󰦅󰚘󱄵度󰎰󰐺󰎱󰩡󰛶󰎛

󰐆2 2󰀎8 15󰀎25 25󰀎30

2 󰠌󰘴󰡐󱊪󱢐󰦴󱍹󰚫󰤱󰜶󰖽󱍹󱕪󰎔󰚕󱀿󰚘󰣍冷󰹠󰎔󰚍󰖟󰖚󰧵不󰗱󰙦󰘴󰎛

3 7 14 30

3 󰚇󰿽󰰏󰰐󰕰󰤏療󱈘󰿓󰕭󰎔󰕀列󰛶󱂈󱢐󰤢󰠠󰚶󰾇󰖟󰹨󰘻尿󰎰proteinuria󰎱󰖗󰢏󱒷󰿽󰰐󱧢惡󰖏󰕰󰜂󰘴󰎛

利尿󱕪 ACE󰞍󰠫󱕪

󱁩離󰕗󰺏󱈐󰥴󱞰󱕪 β-Adrenergic󰥴󱞰󱕪

4 󱓳󰲻󱄫󰷈󱕪󰮴󰎔󰕀列󰻾󰷈󰸴󰙽󰎔󰛶󰥃不󰕵󱄫󰎛

󰖽󰐁󰘲󰤈 󰖽󰐁󰔬󱔧 󱣼󰤈󰐁󰔬󱔧 󲪝󰺾󰤈󰐁󰔬󱔧

5 󱓳󰲻󰜶acacia󰠂󱕪󰎔󱆃󰘴󰕀列󰟷󰔫󱌟󰟻󱍍󱕪󰎛

Benzalkonium chloride Benzoic acid Sorbic acid Parabens

6 󰕀列󰖏療󱢐󰤢󰎔󰛶󰥃󰚇󰿯󰕲󱈘󰿓󰕭不易󰺗󰚫󰵛󰥃󰸂󰘳mucositis󰎛

Fluorouracil Doxorubicin Methotrexate Cisplatin

7 󰕢󰤵󰨬󰵛󰥃󱧯󰖃󰕰󱁪離󰕗󱖺度󰩡130 mEq/L󰎔󰽻離󰕗󱖺度󰩡105 mEq/L󰎔󱈧離󰕗󱖺度󰩡4.5 mEq/L󰎔󰛨糖

󰬖󰩡120 mg/dL󰎔BUN󰩡24 mg/dL󰎔󱓮󰛷󱌩󰠡󰛨󵠚󱋶󰺘󱚘󰪪󰩡若󰕥mOsmol󰎛

270 375 420 485

8 󰾤󱀕󰳓󰱃󰕰penicillin G potassium󰎔󰻈不󰡵󰘴󰕀列󰛶󱌟󰻾󱕪󱍹󰻂󰚫󰣹󰭴󰷈󰎛

Dextrose injection Sodium chloride injection

Sterile water for injection Sodium bicarbonate injection

9 󰕀列󰟷󰔫󱌟󰻾󱕪󰎔󱆃󰘴󰣍󱓳󰲻󱄅󰘳󰠝󰤱󰣹󰭴󱕪󰎛

󰣹󰭴󰘴󰖽 󰾤󱀕󰣹󰭴󰘴󰖽 󰗣󰞍󱀕󱕪󰣹󰭴󰘴󰖽 󰘳理󰬇󱨖󰖽

10 󰕀列󰟷󰔫󱢐󰤢󰕰󰣹󰭴󱕪󰗣󰠩D5W󰢨NS󰧵󰎔󰻈易󰸂󰘳󰞨󱖸󰎛

Diazepam Furosemide Folic acid Ampicillin

11 󰚇󱠔󰳃󱢐󰝝󰖃󱓳󰲻󰤱TPN󰣹󰭴󰷈󰎔󰚘󰣋󰽚󰫻󰩡󰚍󰕆󰎛

3󰕛󰮴 24󰕛󰮴 48󰕛󰮴 72󰕛󰮴

12 󰖏療󱈘󰿓󰕭myelosuppression󰩡󰵄見󰤱不良󰖘󱚨󰎔󰕀列󰛨󰷺󰕭󰗐󰛶󰥃󰠹󱐙󱥼󰻈󱧩󱀑󰎛

󰪦󰛨󰷺 󰘻󰛨󰷺 󰛨󰕛󰣨 󰔿󰥃󱐙󱥼󰿓度󰪌󰙵

13 󰕀列不良󰖘󱚨󱍖󰛨󰷈󱛀󰾓󱂈󰘾󰤱󰲻󱊙󰎔󰛶󰥃󰘥󱒔󰎛

Rhabdomyolysis󰎚CK-MB Hepatotoxicity󰎚BUN/Cr

Hematotoxicity󰎚CBC Neutropenia󰎚RBC count

14 󱠔󰳃󰲾󱊙󰳃󰖃󰳏󰻢󱏝󰤱󱢐󰦴󱁞行󰦛󱟓󰢤󰎰prospective󰎱󰠌󰘴󱀱󰛷󰎔󰽄󰟢󰕰󰎔󱠔󰳃󰨢󰚇󱁞行󰛶󱌟󰪔󰟒󰎛

Drug use evaluation Phase III clinical trial

Post-marketing surveillance Sensitivity analysis

15 󰠉󱖕󰙤󰘧󰳜󰵈󰦅󱙠󱢐󰦴󰿯󰗑󰹵󰡳󰺏󰦞󰎔󰚇󰕀列󰣹󰭴󱕪󰕭󰎔󰛶󰥃󰗱󰘷󰰐󰔳󱥋󰚃󰭮󰕭󰛞行󰣹󰭴󰠌󰘴󰎛

Amikacin Doxorubicin Insulin Potassium chloride

16 󱠔󰮃󱁲列󰏈etoposide 50 mg/m2 󰍪 5󰏉󰹠󰖱󰎔󱢐󰮃󱇠󰚕󰛶󰜒讀󰎛

󰞢󰚻󰿯󰕲50 mg/m2 etoposide󰎔󰞢󰖲󰕶󰚻 󰞢󰖲󰿯󰕲50 mg/m2 etoposide󰎔連󱥛󰕶󰖚

󰞢cycle󰿯󰕲50 mg/m2 etoposide󰎔連󱥛󰕶󰬡cycles 󰹠󰖱󱁲立不󰝙󱖞󰎔󱂊立󰠥󱅃󱄎󱠔󰮃

17 󰚍數󰴏󰖃󰤷󰳴󱢐󰝝󰴚󱄐󱢐󰮃󰣍󰢭󰵷󰳜󰦅󰙌󰗑󱓳󱕪󰹠󰖱󱌧󰮴󰎔󰢓󰢓󰾤󰤄󰠷󰵓󰕀列󰟷󱂈󰲛󰮒󰎔󰫀󰘴󱢐󱔞󱅝󰢤

󱀱󰛷󱈈󱣄󰗐󰝙󱖞󰎛

󰹠󰖱󰖃󰭲 󰰐歷󱊴󰫞 󰰐󰔳󰘴󱢐󰗾 󰰐󰔳󰴗󰘡󱇷料

18 󰪭󰴏FDA󰤱󰏈MedWatch󰏉󰨢󰨐󰕀列󰟷󰔫󱂈󰎛

󰫎󰖮󰻴󰗢󰙼 󰘆󰖮󱠧󱍾󰙼 󱠔󱢐󱇷󰲛󱌻 󱢐󰤢不良󰖘󱚨󰺏󰻴

19 󰕀列󰛶󰥃󰩡B󰧀󱢐󰤢不良󰖘󱚨󰎰type B-ADR󰎱󰎛

󱈘󱕪量󰤱󰝼󱕩󰛨󱕪󱖄󰫀󱄫󰛨 󰔿󱛩󰝼󱐡󱩀󱢐󱖄󰫀󱀮󱤚󱎽󱡶

󰥹󱧶󰱈類󰤱󱈘󰶕󰢤󰙖󰜌 類󰡐󱔧󱢐󱖄󰫀󰪷󱑭󱌌 󰐶󱀦󰇺4104

󰥤󰔛󰇺4󰉡2

20 󰘴󱢐󰨐󱖄󰤱󰖃󰭲󰎔󰕀列󰛶󰥃󰘥󱒔󰎛

󰥯󰽚󰣚󰘴amiodarone󰤱󰰐󰔳󰎔󱚨󰡳󰽚󱛀󰾓󰿽󰕂󱆯󰗤󰱨 󱚨󰶒󰟛󰣚󰘴clopidogrel󰤱󰰐󰔳󰎔󰡳󰽚󱌑󰾓INR 󰣚󰘴ticlopidine󰤱󰰐󰵛󰎔󱚨󰡳󰽚󱛀󰾓󰛨󰪦󰱈󰎔󰗐󱝩󰜍󰺆󰛨󰿇󰘳 󱚨󰼼󱙌󰰐󰔳󰝄󰢨󰥎󱀑󰜶󰘴nitroglycerin󰛡󰕀󱙍󰎔󰗐󰜍󰛨󱚘󰕀降󱈘󱏣󰛖󰺗󰚫暈󰰞 21 林老󰙣󰘳󰚂󰩡󰘈󰰠󰼉󱠔󰎔󱠔󰮃󰹠󰖱Stilnox®󰎰zolpidem󰎱󰗐󰞏󰿳󰠡󱌕󰰠󰎔󱠔󰮃󰜗理󰚇󱖙󰜂󱈽󱆰󰮴󰦥󱎄󱙇了Starlix®󰎰nateglinide󰎱󰎔󰚕󰣠󱢐󰮃󰘢󰱨󱊘󱤚󰘈󱎄󰤱󱇩󰎔林老󰙣󰘳󰗱󰱨󱄎󰠹󰭭󰣍󰎚 󰛨糖󱈘󰜅󰛖暈󱢩 󰛨󱚘󱈘󰜅󰛖󰙖󰜌 󰖨󱈂󱈘󰺒󰛖󰣖󰲮 󱍎󰱞󰾤󰤄󰚯󱜍󰛖󰶈尿󰜺󱣄 22 󰠌󰘴captopril󰤏療󰳏󰛨󱚘󰎔󱢐󰮃󱚨󰜫󰤵󰰐󰔳󰕀列󰛶󰠃󰎛

󱏁󰫞󰮴󰣚󰘴 󰗱󰱨󰖧󰲦󰦯󱉬 󱍖󰬇󰤢󰣚󰘴 󱏁󱇖󰗚󱈧 23 󰕀列󰝼󰘳󰱈󰎔󰛶󰥃󱆃󰘴󰣍󱄅󰘳󰠝󰖗󰘔󰠝󰎛

Amoxicillin Cefaclor Gentamicin Tetracycline 24 󰚕󰣠󰜃󰫞󱛧󰵓󰪭󰴏󱍹󰺗󰳸󰸂󰦴󰤱󰖃󰭲󰎔󰻈󰭲易󰵕󰕀列󰛶󰥃󰠷󰵓󱇷󰲛󰎛

Remington’s Pharmaceutical Science Facts and Comparison Physicians’ Desk Reference Extra Pharmacopoeia 25 󱢐󰮃󱊙󱆖cyclophophamide󰎰Cytoxan®󰎱󰖏療󰕰󱛮󰰑󰰐󰵛󰎔󱁞行󰘴󱢐󰨐󱖄󰮴󰎔󰕀列󰛶󰥃不󱔞󱅝󰎛 若󰚶󰛨尿󰿇󰘳󰎔󱚨立󰜛󰜫󰤵󱠔󰘳 若󱃢󱤚󱆩󰪷不󱔞󰎔󲭫󰖨󰎕󱉭󰙷󰮴󰎔󰛞行󰳖󱢐󰧵󰎔󰙦󰜫󰤵󱠔󰘳 󰣚󱢐󰽚󱁴󰎔󰞢󰖚󱚨󰕕量󱇖󰗚󰖽󰖉󰎔󱏺󰗣󰶈尿量 若󰚶不󰘥󰵄󰤱󱅟󰥹󰿇󰘳󰮴󰎔󱚨立󰜛󰜫󰤵󱠔󰘳 26 󰕀列󰟷󰔫󱌟󰝼󰘳󰱈󰎔不󱂊󰠉󰿽󱦬󰗤󰱨󱓳󱖞󱕪量󰎛

Ciprofloxacin Imipenem Nafcillin Tobramycin 27 󰕀列󱢐󰦴󰕭󰎔󰛶󰥃󰨢CYP3A4󰻈󰵎󰤱󱎈󱖄󱕪󰎰inducer󰎱󰎛

Erythromycin Rifampin Rifapentine Rifabutin 28 Ketoconazole󱍖omeprazole󰙽󰠓󰠌󰘴󰮴󰎔󰗱󰱨󰸂󰘳󰙌󰕵󰜂󰘴󰕰󱖲󰠫󰩡󰛶󰎛

󰞏󱧢󰪷󰕭󰕰󱎨󱨕度󰛖󰾇󰖟ketoconazole󰕰󰜮󰚯 󰾇󱒷󰪷󱆩󱤘󰳯󰛖󱏺󰗣ketoconazole󰕰󰜮󰚯 󰞍󰠫󰪷󱆩󱈐󰕰󰘥󰵄󱀕落󰛖󱏺󰗣omeprazole󰕰󰜮󰚯 󱏺󰗣󰪷󱆩󱤘󰳯󰛖󰾇󰖟omeprazole󰕰󰜮󰚯 29 󰕀列󰛶󰸴󱢐󰤢󰎔󰢖󰚼󰚂󱤁󰤞󰢤󱍖󰘻󰹨󰘻󰎰albumin󰎱󰿨󰙽󰎔󰛖󱐙󱥼󱢐󰤢󰚇󱧯󰖃󰕰󰖉󰜉󰎛

MAOIs󰐀tyramine Digoxin󰐀antibiotics Warfarin󰐀phenobarbital Phenytoin󰐀valproic acid 30 Theophylline󱍖ciprofloxacin󰙽󰠓󰠌󰘴󰮴󰎔󰢬󰸂󰘳󰕰󱐙󱥼󰩡󰛶󰎛

Theophylline󰣍󱧯󰖃󰕰󰖉󰜉󱧯󱗨󱏺󰗣 Theophylline󰕰󰛨󰕭󱢐󰤢󱖺度󰕂󰖒 Ciprofloxacin󱎈󱖄󰟗󱦬󱎧󰱈󰗖󱝔 Ciprofloxacin󰕰󰘳󱧯󰗱󰘴率󰕀降 31 󰗆󰙣󰘳󰚂󰖨󰲐󱌣󰙽󰠓󰥄󰖽󱆭󰔵󰳃󰎔󱠔󰮃󰹠󰖱󰕑󰣚digoxin 0.125 mg qd󰎔󰚂󰿽󰗤󰱨󰘥󰵄󰶂󰛷󰠡digoxin󰗪󰲐